rs578776
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Gene polymorphisms of CHRNA3 (rs578776) and CHRNA4 (rs1044396 and rs2229959) were associated with the success of smoking cessation after the diagnosis of lung cancer, which should be considered in the management of smoking cessation after patients are diagnosed with lung cancer.
|
31402126 |
2020 |
rs34424986
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin.
|
31285534 |
2020 |
rs1044396
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gene polymorphisms of CHRNA3 (rs578776) and CHRNA4 (rs1044396 and rs2229959) were associated with the success of smoking cessation after the diagnosis of lung cancer, which should be considered in the management of smoking cessation after patients are diagnosed with lung cancer.
|
31402126 |
2020 |
rs121912654
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
|
31067569 |
2020 |
rs139600787
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin.
|
31285534 |
2020 |
rs2229959
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Gene polymorphisms of CHRNA3 (rs578776) and CHRNA4 (rs1044396 and rs2229959) were associated with the success of smoking cessation after the diagnosis of lung cancer, which should be considered in the management of smoking cessation after patients are diagnosed with lung cancer.
|
31402126 |
2020 |
rs2239611
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among individuals older than 50 years, we observed a protective effect of rs2284749 in the recessive model (P = 0.020) and log-additive model (P = 0.045), and rs2239611 associated with the decreased lung cancer risk under codominant (P = 0.037), dominant (P = 0.010), overdominant (P = 0.026) and log-additive (P = 0.015) models.
|
31794515 |
2020 |
rs2284749
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among individuals older than 50 years, we observed a protective effect of rs2284749 in the recessive model (P = 0.020) and log-additive model (P = 0.045), and rs2239611 associated with the decreased lung cancer risk under codominant (P = 0.037), dominant (P = 0.010), overdominant (P = 0.026) and log-additive (P = 0.015) models.
|
31794515 |
2020 |
rs483352697
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
|
31067569 |
2020 |
rs756402191
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
|
31067569 |
2020 |
rs776983107
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin.
|
31285534 |
2020 |
rs778009684
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin.
|
31285534 |
2020 |
rs1052133
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using the multifactor dimensionality reduction method, we found a model of gene-gene interactions associated with the risk of lung cancer: NBS1 (rs1805794)-XRCC1 (rs25487)-hOGG1 (rs1052133)-XPG (rs17655).
|
31584889 |
2019 |
rs1052133
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To analyze the relationship of GSTT1, GSTM1, XRCC1 (rs25487), ERCC1 (rs11615, rs3212986), ERCC2 (rs13181), XRCC3 (rs861539), OGG1 (rs1052133), and Alpha-1-Antitrypsin mutations (AAT) with the risk of lung cancer in never-smokers, and ascertain if there is an effect modification between these polymorphisms and residential radon exposure.
|
31446980 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells.
|
31426517 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology.
|
31207149 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative.
|
30810279 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative.
|
30810279 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology.
|
31207149 |
2019 |
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |